Glioma Treatment with AZD6244 – Phase I/II

PBTC-029B: Study of AZD6244 for Recurrent or Refractory Pediatric Low-Grade Glioma

Protocol Description

Through this Pediatric Brain Tumor Consortium investigation, researchers will study the effects of selumetinib (AZD6244) in treating or re-treating young patients with a low-grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Researchers believe that AZD6244 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.
Study Level: Phase I/II

Eligibility Criteria

Subject to certain exclusion criteria, this study is enrolling pediatric patients who have a progressive, recurrent or refractory low-grade glioma or non-optic pathway pilocytic astrocytoma.
Males and Females: Ages 3 to 21 years


Participants in this study will take AZD6244 twice daily in 4-week courses that follow continuously for up to 26 courses. Medical examinations, including blood testing and neurologic assessments will be required at the beginning of each course, and imaging assessments will be done every 3 months.
Visits: Up to 26
Duration: Approximately 2 years

Status: Open for Enrollment

Source(s) of Support

National Cancer Institute
Pediatric Brain Tumor Consortium (PBTC-029B)

Primary Investigator

James Felker, MD

Contact Information

For more information about the study or enrollment, please contact:
Research Coordinator Sharon Dibridge